logo
  

WHO Issues Updated Emergency Use Listing For Novavax's Nuvaxovid COVID-19 Vaccine

The World Health Organization or WHO has issued an updated Emergency Use Listing for Nuvaxovid (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent COVID-19 caused by the SARS-CoV-2 as a primary series of two doses in adolescents aged 12 through 17 and as a booster in adults aged 18 and older, Novavax Inc. (NVAX) said in a statement.

Nuvaxovid (NVX-CoV2373) is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2.

In the 12 through 17-year-old population, Novavax' vaccine has been authorized in more than 10 markets including the U.S., the European Union, and the U.K. The vaccine has also been authorized as a booster in the U.S., EU, Japan, Australia, New Zealand, and Switzerland, and a number of other countries have policy recommendations allowing use of the vaccine as a heterologous or homologous booster dose.

The WHO previously granted EUL for Nuvaxovid in adults aged 18 and older in December 2021.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
Follow RTT